Home › Research › Topics › pet
pet
1,163 studies tagged pet, dated 1983-08-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Large-scale head-to-head comparison of on- and off-target profiles of [18F]Tauvid and [18F]MK6240 tau-PET in aging and Alzheimer’s disease 2026-11-01
- Detection of tau spatial extent using MK6240 and flortaucipir PET 2026-10-28
- Soluble amyloid composition links proximal APP processing, fibrillar burden and the p-tau181 response 2026-10-22
Studies
1,163 studies carry this tag.
Date range
1983 to 2026
Top journals
- Neurology 88
- Alzheimer's & dementia : the journal of the Alzheimer's Association 58
- Brain : a journal of neurology 52
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine 52
- Alzheimer's research & therapy 34
337 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care.
-
Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography.
-
18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs).
-
Compared to controls, all three clinical groups showed a pattern of mainly increased referenced standard uptake values (SUVR) for the amyloid tracer [18F]-AV45 PET, with rank order PTSD > TBI_PTSD > TBI > Control, and same rank order was seen in the deficits of cognitive functions.
-
Within the training set, individuals closer to or beyond their parent's symptom onset demonstrated reduced grey matter volume and altered functional connectivity, specifically in regions known to be vulnerable in Alzheimer's disease.
-
Although brain neuroinflammation may play an instrumental role in the pathophysiology of Alzheimer's disease, its actual impact on disease progression remains controversial, being reported as either detrimental or protective.
-
While prior work reliably demonstrates that the APOE ɛ4 allele has deleterious group level effects on Alzheimer disease pathology, the homogeneity of its influence across the lifespan and spatially in the brain remains unknown.
-
The concentration of 124 I-RmAb158-scFv8D3, as measured in vivo with PET, increased with age and corresponded well with the ex vivo autoradiography and Aβ immunohistochemistry results.
-
Future research should examine whether minimizing drawbacks at the pre-imaging stage has adverse consequences on results disclosure.
-
There is no disease-modifying treatment currently available for AD, one of the more impacting neurodegenerative diseases affecting more than 47.5 million people worldwide.
-
PET can evaluate amyloid expansion from cortex to subcortex.
-
Analyses revealed high overlap between components, regional and quantitative hypoperfusion, and hypometabolism in patients with AD compared with HC participants in precuneus, parietal, temporal, and occipital cortex.
-
Acupuncture has been used in the therapy of Alzheimer disease (AD); however, its neural mechanisms are still unclear.
-
These results support the feasibility of bridging of clinical trials in the prodromal stage of AD between Asia and western countries.
-
Biomarkers useful for the predementia stages of Alzheimer's disease are needed.
-
At a group-wise level, observable rates of short-term serial tau accumulation were only seen in the presence of abnormal amyloid.
-
Improved prediction of progression to Alzheimer's Disease (AD) among older individuals with mild cognitive impairment (MCI) is of high clinical and societal importance.
-
Simultaneously evaluating resting-state brain glucose metabolism and intrinsic functional activity has potential to impact the clinical neurosciences of Alzheimer Disease (AD).
-
Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying individuals as "positive" or "negative" for biomarkers related to the core pathology of β-amyloid (Aβ).
-
Among the 12 patients with PPA syndrome, 8 (66.7%) were considered as amyloid positive.
-
52/100
Age-related hippocampal sclerosis may account for a significant proportion of elderly participants with amnestic dementia.
-
Memory decline accompanies Aβ accumulation in otherwise healthy, Aβ-negative older adults.
-
To develop a new method for measuring Alzheimer's disease (AD)-specific similarity of cortical atrophy patterns at the individual-level, we employed an individual-level machine learning algorithm.
-
CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less-than-perfect correspondence is expected.
-
Inclusion criteria included clinical diagnosis of PPA; availability of complete speech, language, and cognitive testing; magnetic resonance imaging performed within 6 months of the cognitive evaluation; and PET carbon 11-labeled Pittsburgh Compound-B or florbetapir F 18 brain scan results.
-
The amyloid β subgroups did not differ for any psychobehavioural, cognitive, actigraphy, and structural and functional neuroimaging results after adjustment for age, sex, and level of education More participants positive for amyloid β deposition had the APOE ε4 allele (33 [38%] vs 29 [13%], p 1-42 concentration in CSF significantly correlated with mean 18 F-florbetapir uptake at baseline (r=-0·62, p 1-42 to amyloid β 1-40 (r=-0·61, p 18 F-florbetapir uptake at baseline (mean standard uptake value ratio 1·46 [SD 0·16] vs 1·02 [SD 0·20]), and more were carriers of the APOE ε4 allele (three [75%] of four vs 33 [39%] of 83).
-
All three schemes estimated stages that were significantly associated with amyloid status and when dichotomized to tau positive or negative were 90% to 94% concordant in the populations identified.
-
In this publication, we report cognitive and clinical data as well as apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) biomarker results of the first 394 baseline data sets.
-
We found a sequence to pathological changes, with rates of Aβ deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18·9 years [SD 3·3] before expected onset), followed by hypometabolism (14·1 years [5·1] before expected onset), and lastly structural decline (4·7 years [4·2] before expected onset).
-
We found that distinct sphingolipid species including sphingomyelin (SM) with acyl residue sums C16:0, C18:1, and C16:1 (SM C16:0, SM C18:1, SM C16:1) and hydroxysphingomyelin with acyl residue sum C14:1 (SM (OH) C14:1) were consistently associated with severity of AD pathology at autopsy and AD progression across prodromal and preclinical stages.
-
Alzheimer's disease (AD) is a major neurodegenerative disease and the most common cause of dementia.
-
Apraxia of speech is a motor speech disorder characterized by combinations of slow speaking rate, abnormal prosody, distorted sound substitutions, and trial-and-error articulatory movements.
-
B/AA individuals had elevated CP and HC SUVR (p < 0.007), whereas other ROI SUVR and HC SUVR covaried for CP SUVR did not show race differences (p > 0.05).
-
The aberrant accumulation of the amyloid protein is a critical and early event in the Alzheimer's disease (AD) cascade.
-
39/100
Amyloid plaques are a neuropathologic hallmark of Alzheimer's disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET).
-
Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia.
-
The Study of Knowledge and Reactions to Amyloid Testing, a substudy of an AD prevention trial, involved 2 semistructured telephone interviews with 80 participants recruited from 9 study sites: 50 received elevated and 30 received not elevated amyloid PET scan results.
-
The study objective was to evaluate the safety and efficacy of deep brain stimulation (DBS) at the ventral capsule/ventral striatum (VC/VS) region to specifically modulate frontal lobe behavioral and cognitive networks as a novel treatment approach for Alzheimer's disease (AD) patients.
-
The vascular hypothesis of Alzheimer's disease (VHAD) was proposed 24 years ago from observations made in our laboratory using aging rats subjected to chronic brain hypoperfusion.
-
Over the past decade, a surge of evidence has documented various pathological processes in the retina of patients suffering from mild cognitive impairment, Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases.
-
Generated MR images from florbetapir PET showed signal patterns that were visually similar to the real MR. The structural similarity index between real and generated MR was 0.91 ± 0.04.
-
The medial temporal lobe (MTL) is an early site of tau accumulation and MTL dysfunction may underlie episodic-memory decline in aging and dementia.
-
Reference region selection is important for proper amyloid PET analysis, especially in subcortical vascular dementia (SVaD) patients.
-
43/100
Alzheimer's disease (AD) is a frequently observed, irreversible brain function disorder among elderly individuals.
-
Amyloid positron emission tomography ([18F] florbetaben (FBB) PET) can be used to determine concomitant Alzheimer's disease (AD) in idiopathic normal pressure hydrocephalus (iNPH) patients.
-
Alzheimer's disease (AD), characterized by progressive cognitive decline, is the most prevalent neurodegenerative disease in the elderly.
-
Accumulation of paired helical filament tau contributes to neurodegeneration in Alzheimer's disease (AD). 18 F-flortaucipir is a positron emission tomography (PET) radioligand sensitive to tau in AD, but its clinical utility will depend in part on its ability to predict cognitive symptoms in diverse dementia phenotypes associated with selective, regional uptake.
-
Previous MRI studies reported cortical iron accumulation in early-onset (EOAD) compared to late-onset (LOAD) Alzheimer disease patients.
-
The highly consistent regional hierarchy of PET-evidenced amyloid deposition across participants resembles neuropathologic observations and suggests a predictable regional sequence that may be used to stage an individual's progress of amyloid pathology in vivo.
-
[ 18 F]-AV-1451 is a leading tracer used with positron emission tomography (PET) to quantify tau pathology.
From across this tag
10 of the 1,159 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Alzheimer's Disease and Frontotemporal Dementia: A Robust Classification Method of EEG Signals and a Comparison of Validation Methods
- Anterior-temporal network hyperconnectivity is key to Alzheimer’s disease: from ageing to dementia
- A pilot study of fluorescence lifetime imaging ophthalmoscopy in preclinical Alzheimer's disease
- Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition
- EEG SIGNAL ANALYSIS FOR CLASSIFYING ALZHEIMER’S AND FRONTOTEMPORAL DEMENTIA DISORDERS USING ENSEMBLE METHODS
- Artificial intelligence in brain MRI analysis of Alzheimer's disease over the past 12 years: A systematic review
- A data-driven regional amyloid PET score predicts cognitive decline beyond Centiloid
- Random Forest Algorithm for the Classification of Neuroimaging Data in Alzheimer's Disease: A Systematic Review
- Diffusion Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort
- 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging